Compare
Gilead Sciences vs Protagonist Therapeutics (GILD vs PTGX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Protagonist Therapeutics (PTGX) +69.5%; so far this year the figures are +36.0% and +51.2%.
Gilead Sciences is the larger company by market value, about 24.0 times the size of Protagonist Therapeutics.
Revenue grew +6.5% at GILD and +163.7% at PTGX over the last year.
GILD yields 1.95%. PTGX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | PTGX | |
|---|---|---|
| Price | $166.89 | $132.04 |
| 1-day | -0.41% | -2.38% |
| YTD | +35.97% | +51.18% |
| 1 year | +36.15% | +69.54% |
| 3 years | +108.12% | +773.86% |
| Market cap | $207.0B | $8.6B |
| P/E | — | 28.0 |
| P/S | 6.68 | 15.62 |
| P/B | 15.87 | 7.94 |
| Revenue growth | +6.50% | +163.70% |
| EPS growth | -149.00% | +624.60% |
| Gross margin % | 79.9 | — |
| Net margin % | -12.5 | 62.0 |
| ROE % | -29.6 | 31.5 |
| Debt / equity | 2.01 | 0.01 |
| FCF yield % | 6.7 | 1.3 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.93 |
| RSI (14) | 60.2 | 39.0 |
| Technical rating |